Member Info for Cuddles48

Don’t be daft no one will have world rights to add graphene to tarmac. !!!!!!

Yes by the sounds of it graphene in tarmac could be coming to a road in Gloucestershire soon.

https://youtu.be/rrGz7EL09os

I don’t that when the market gets knowledge of potential milestone payments ans carry trades potential, then the company should be reappraised for its long term market value. This has never been on the balance sheet to date.

So the market met be surprised.

https://www.linkedin.com/feed/update/urn:li:activity:6803316354062655488?commentUrn=urn%3Ali%3Acomment%3A%28activity%3A6803316354062655488%2C6803424327174770688%29

You are so wrong it needs high quality graphene or it doesn’t work that’s from the horses mouth !!!

Surely this has to change the cementiment !!!!??

Remember Buy low sell high that’s what the market makers do ans they try to engineer it that most holders panic into doing just the opposite.

Beat them at their own game.

And one tiny buy and offer leaps up.

Surely this should be attracting new investors who can buy in much cheaper than where. This was only a couple of weeks ago nothing has changed. Bargain prices as the market makers have walked it down to try to gather stock from weak holders.

Time for bottom feeders to gather some cheap stock. Can sell loads at 131 can only buy a few on the offer. One MM at 135 then three at 145. Shoes they don’t want to sell.

Looks like a shake by the city to grab stock. We know they plan to release more information about all the milestone payments and carries on various drugs in clinical trials. They have stated they will release this as part of results. As none of these potential milestone payments or potential royalties have been added to the balance sheet. We may see an upgrade in the perceived company valuation feom this new data and that’s how the board plans to create shareholder value.

It was hinted at being potentially substantial on likely hood that a good percentage of the drugs will likely get to clinic. On historic average data.

The company has always underpromised on this so it has never been considered in the valuation.

I’m told they hope to issue the results earlier than last year aiming for July.

But other news All linked to the OptiMAL library platform Covid-19, PD-1 and TIGIT + 4th target could be anytime.

When is the market going to wake up to this share.

2 deals for over $1 billion in its sector today alone.

Just shows how massively undervalued FAB is.

https://amp-ft-com.cdn.ampproject.org/c/s/amp.ft.com/content/68fcea54-d90b-442b-860a-028036d272fd

May be worth looking into the IcanoMAB latest antibody for ARDs and COVID. As it was developed by MAB discovery with whom FAB worked on a collaboration back in the day before Biontech took over MaB Discovery. Maybe a carry benefit to FaB if this gets to market.

The successful production of control models has been achieved and the process for full screening against new targets requires further optimisation to increase efficiency of the selection process. Work has also been commenced on two further oncology targets to be developed in addition to the SARS-CoV-2 work.

Wouldn’t want to be out of this now.

In his podcast yesterday, Zak Mir has a 3/4 month target of 330p if we can break 172p. He actually comments about the difficulty in buying stock and yet SP slow to rise.

Been told to email
Aimregulation@lseg.com

Suggest you all also complain. Our share price is being manipulated and held artificially low for some reason n

Let’s call these bastards out.

Can’t people see what’s occurred hear in my opinion.

I believe over the past few months the market makers have accumulated a rather large short position on their books. And the tipping point is almost upon them. They are now unable or seriously susceptible to any more shorts and have fear of being able to cover at profitable prices. So they need to only put on new shorts at much higher prices hence the jump to 177p and 185p for the next few thousand shares if nobody sells them any stock.

The availability of free float shares is now probably so so small they fear being completely unable to cover without creating a huge spike. hence the desperate need to completely stop any buying.

Also they know news is very close with the end of year results due ans surely an update on the COVID antibody. If they are good the MM are absolutely buggered and could lose some serious money.

So it will be very interesting to see if a short squeeze can be triggered on the next wave of buying from any new or top up investors.

It’s going to be very interesting.

Can anyone explain what’s occurring with he market here. I’ve never known such a long period of NT trades yet there have been very few big buys actually going through.

So why are market makers so afraid to offer shares

All dummy trades today have no price on amounts up to 3000 and after that amounts up to 25,000 was quoted at 177 to buy over that it was up to 184.99.

That clearly implies a massive shortage of stock !!

But if that’s the case why aren’t the market makers offering better prices to sell stock as clearly no one wants to sell many at the quoted prices.

Anyone got any ideas

FAB
Only 50 shares on offer at 162 then nothing until 177
That?s 9.25% up lift
I?ve never seen this on any share before.
MM must be buggered.
Any buys will move this seriously higher.

Never seen this before on a dummy trade to buy up to 3000 shares I?m quoted 162 but make it 3001 and it jumps to 177 ?
Must be one MM on at 162 for max 3000 then no offers until 177.
Anyone else notice this.